It is an intermediate for Relugolix and Rufinamide. Relugolix is a gonadotropin-releasing hormone antagonist (GnRH receptor antagonist) medication which is used in the treatment of prostate cancer in men and uterine fibroids in women.
Rufinamide is used with other medication(s) to control seizures in people who have Lennox-Gastaut syndrome (a severe form of epilepsy that begins during childhood and causes several types of seizures, behavioural disturbances, and developmental delays). Rufinamide is in a class of medications called anticonvulsants.
Looking for similar products? Visit Product Comparison Guide
We also manufacture the Relugolix and Rufinamide and the following intermediates:
Name of the Material | CAS NO. |
---|---|
2,6-DIFLUOROBENZYL Chloride | 697-73-4 |
4-Nitrophenylaceticacid | 104-03-0 |
Methyl-2-(4-Nitrophenyl)Acetate | 2945-08-6 |
An ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and GMP Certified Company
Treatment of prostate cancer in men and uterine fibroids in women.